Acumen Pharmaceuticals (ABOS) vs Estrella Immunopharma (ESLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 78.9% versus a loss of 88.1%. Over five years, ESLA leads with a -96.8% price change compared with -97.7% for ABOS. Estrella Immunopharma is the larger company by market cap ($14.1 million vs $13.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | ESLA |
|---|---|---|
| Share price | $0.1865 | $0.321 |
| Market cap | $13.49M | $14.11M |
| 1-day change | -3.52% | -5.70% |
| YTD return | -91.16% | -79.42% |
| 1-year return | -88.12% | -78.88% |
| 5-year return | -97.74% | -96.78% |
| EPS (TTM) | $-1.55 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-121.33M | $-13.06M |
| 52-week high | $3.60 | $2.27 |
| 52-week low | $0.16 | $0.24 |
| Distance from 52-week high | -94.82% | -85.86% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +3975.07% | +3638.32% |
| Average volume | 2.73M | 2.04M |
| Shares outstanding | 72.33M | 43.97M |
| Employees | 60 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ABOS vs ESLA FAQ
Which is bigger, Acumen Pharmaceuticals or Estrella Immunopharma?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $14.11M compared with $13.49M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or ESLA?
ESLA returned -78.88% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Estrella Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.